William Blair Issues Optimistic Outlook for Labcorp Earnings

Labcorp Holdings Inc. (NYSE:LH) – Equities researchers at William Blair lifted their Q1 2026 earnings per share (EPS) estimates for shares of Labcorp in a research report issued to clients and investors on Wednesday, October 29th. William Blair analyst A. Brackmann now expects that the medical research company will earn $3.98 per share for the quarter, up from their prior forecast of $3.97. The consensus estimate for Labcorp’s current full-year earnings is $16.01 per share. William Blair also issued estimates for Labcorp’s Q3 2026 earnings at $4.42 EPS.

Labcorp (NYSE:LH) last announced its earnings results on Tuesday, October 28th. The medical research company reported $4.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.13 by $0.05. Labcorp had a return on equity of 15.85% and a net margin of 6.21%.The firm had revenue of $3.56 billion during the quarter, compared to analyst estimates of $3.56 billion. During the same quarter in the prior year, the company earned $3.50 EPS. The business’s revenue was up 8.6% compared to the same quarter last year. Labcorp has set its FY 2025 guidance at 16.150-16.500 EPS.

A number of other analysts have also recently commented on LH. Truist Financial set a $320.00 target price on shares of Labcorp in a report on Tuesday, October 14th. UBS Group dropped their target price on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Barclays boosted their target price on shares of Labcorp from $275.00 to $290.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Finally, Mizuho boosted their target price on shares of Labcorp from $285.00 to $320.00 and gave the company an “outperform” rating in a report on Friday, October 17th. Eleven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $295.54.

Labcorp Stock Down 2.1%

Shares of NYSE:LH opened at $252.55 on Monday. Labcorp has a 52-week low of $209.38 and a 52-week high of $293.72. The firm has a market capitalization of $20.99 billion, a P/E ratio of 24.81, a P/E/G ratio of 1.59 and a beta of 0.89. The stock has a 50 day moving average price of $275.96 and a 200-day moving average price of $262.06. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.55.

Institutional Trading of Labcorp

A number of institutional investors and hedge funds have recently modified their holdings of LH. Vontobel Holding Ltd. lifted its position in shares of Labcorp by 7.9% in the second quarter. Vontobel Holding Ltd. now owns 3,057 shares of the medical research company’s stock valued at $802,000 after acquiring an additional 225 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Labcorp by 1.3% in the second quarter. Sequoia Financial Advisors LLC now owns 145,977 shares of the medical research company’s stock valued at $38,320,000 after acquiring an additional 1,816 shares in the last quarter. D.A. Davidson & CO. lifted its position in shares of Labcorp by 12.7% in the second quarter. D.A. Davidson & CO. now owns 13,358 shares of the medical research company’s stock valued at $3,507,000 after acquiring an additional 1,507 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Labcorp by 11.7% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 210,102 shares of the medical research company’s stock valued at $55,154,000 after acquiring an additional 22,018 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Labcorp by 2.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,000,828 shares of the medical research company’s stock valued at $528,739,000 after acquiring an additional 43,509 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Activity at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,643 shares of Labcorp stock in a transaction on Monday, August 11th. The stock was sold at an average price of $266.78, for a total value of $1,505,439.54. Following the completion of the sale, the chief executive officer owned 93,319 shares of the company’s stock, valued at approximately $24,895,642.82. This trade represents a 5.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richelle P. Parham sold 7,009 shares of Labcorp stock in a transaction on Friday, October 31st. The stock was sold at an average price of $254.28, for a total value of $1,782,248.52. Following the completion of the sale, the director directly owned 2,469 shares of the company’s stock, valued at approximately $627,817.32. The trade was a 73.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 16,555 shares of company stock valued at $4,347,040 in the last 90 days. Corporate insiders own 0.84% of the company’s stock.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Wednesday, November 26th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, November 26th. Labcorp’s dividend payout ratio (DPR) is 28.29%.

About Labcorp

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.